119 related articles for article (PubMed ID: 19901011)
1. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study.
Mocikova H; Obrtlikova P; Vackova B; Trneny M
Ann Oncol; 2010 Jun; 21(6):1222-1227. PubMed ID: 19901011
[TBL] [Abstract][Full Text] [Related]
2. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
3. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
4. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
5. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
[TBL] [Abstract][Full Text] [Related]
7. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma.
Meany HJ; Gidvani VK; Minniti CP
Pediatr Blood Cancer; 2007 Apr; 48(4):399-402. PubMed ID: 16514616
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
9. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
10. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
[TBL] [Abstract][Full Text] [Related]
11. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.
Hutchings M; Mikhaeel NG; Fields PA; Nunan T; Timothy AR
Ann Oncol; 2005 Jul; 16(7):1160-8. PubMed ID: 15939713
[TBL] [Abstract][Full Text] [Related]
13. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
14. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma.
Crocchiolo R; Fallanca F; Giovacchini G; Ferreri AJ; Assanelli A; Verona C; Pescarollo A; Bregni M; Ponzoni M; Gianolli L; Fazio F; Ciceri F
Ann Hematol; 2009 Dec; 88(12):1229-36. PubMed ID: 19468730
[TBL] [Abstract][Full Text] [Related]
15. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
16. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
17. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.
Castagna L; Bramanti S; Balzarotti M; Sarina B; Todisco E; Anastasia A; Magagnoli M; Mazza R; Nozza A; Giordano L; Rodari M; Rinifilo E; Chiti A; Santoro A
Br J Haematol; 2009 May; 145(3):369-72. PubMed ID: 19344403
[TBL] [Abstract][Full Text] [Related]
19. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.
El-Galaly TC; Mylam KJ; Brown P; Specht L; Christiansen I; Munksgaard L; Johnsen HE; Loft A; Bukh A; Iyer V; Nielsen AL; Hutchings M
Haematologica; 2012 Jun; 97(6):931-6. PubMed ID: 22207683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
